Introduction {#s02}
============

No cell is an island ([@bib163]). Indeed, the vertebrate immune system---with its reliance on intercellular communication and functional interdependence---epitomizes this principle. Yet recent work with single-cell transcriptomics, proteomics, and mathematical modeling has revealed that most nucleated cells also possess a deeply interconnected responsivity of their own ([@bib129]; [@bib148]). This network often galvanizes hundreds of host defense proteins to guard diverse tissues or portals of entry, and operates on a nanoscopic rather than a macroscopic scale ([@bib88]).

The ability of individual cells to marshal such broad-based defense programs is known as cell-autonomous immunity ([@bib11]; [@bib128]). In addition to providing a barrier to infection, cell-autonomous immunity integrates homeostatic signals to ensure the maintenance of key housekeeping functions and genome integrity. Why is such integration necessary? Because as organismal lifespan increases, recurring threats to cellular homeostasis accumulate for the host ([@bib83]). Here, repeated encounters with microbial pathogens or nonmicrobial allergens, toxins, venoms, and other xenobiotics represent external threats ([@bib118]; [@bib128]), whereas intrinsic challenges arise from endogenous retroelements that promote oncogenesis or from metabolic disturbances that elicit inflammatory sequelae ([@bib64]; [@bib109]; [@bib55]). Each of these challenges is closely monitored by the innate and adaptive immune systems to restrict infection or cellular transformation and to mobilize repair mechanisms that help refurbish damaged tissue.

Among the most effective containment strategies used by longer-lived vertebrates are those elicited by the IFN family of cytokines. IFNs drive complex homeostatic defense networks comprising several hundred IFN-stimulated genes (ISGs; [@bib88]; [@bib133]). Some ISGs exhibit direct microbicidal activity while others influence neoplastic progression through their antiproliferative or immune-editing effects ([@bib88]; [@bib133]; [@bib120]; [@bib107]). Recent work has identified a family of IFN-inducible GTPases---the 65--73 kD guanylate-binding proteins (GBPs)---as a major nexus of this defensive repertoire ([@bib66], [@bib67]). GBPs confer protectant functions against phylogenetically diverse pathogens and cooperate with the core inflammasome machinery to orchestrate pyrogenic cytokine production and pyroptosis. These activities impact localized microbial encounters as well as systemic derangements, for example during Gram-negative sepsis ([@bib40]). They also extend to microbiota-driven inflammatory diseases and cancer.

This review examines the newly emerging roles played by GBPs in protective immunity with an emphasis on cell-autonomous defense and inflammasome-driven responses during infection, inflammation, and cancer. Where appropriate, GBP activities in humans will be highlighted to underscore the clinical and therapeutic implications of these increasingly important immune proteins.

GBPs in humans and other vertebrates {#s03}
====================================

GBPs arose early in the eukaryote lineage, as shown by Hidden Markov Modeling that revealed 132 intact *GBP* genes across 32 taxa ([@bib142]). Bona fide orthologues exist not only in vertebrates and cephalochordates but also protists, amoebae, plants, and algae ([Fig. 1](#fig1){ref-type="fig"}). Hence the birth of GBPs predates IFN signaling, with their primordial defense functions being refashioned in early gnathostomes (jawed vertebrates) to respond to cytokine stimulation ([@bib66]; [@bib42]; [@bib137]). Despite differences in inducibility, a consistent feature across most species is the expansion of *GBPs* into chromosomally clustered multigene families that include as many as 16 paralogues in *Paramecium tetraurelia* ([@bib75]; [@bib142]; [Fig. 1](#fig1){ref-type="fig"}).

![**GBPs are ancient and widely distributed in eukaryotes.** A comprehensive in silico scan of 91 taxa from [@bib142] plus newer deposits yielded this circular dendrogram with emphasis on human GBP-related orthologues. Sequences were aligned with the E-INS-i algorithm (MAFFT v7) and taxa with incomplete data removed via MaxAlign version 1.1. Right: The phylogenetic tree was constructed using a modified version of the unweighted pair group method with arithmetic mean clustering as implemented by MAFFT. Left: A TimeTree diagram (<http://www.timetree.org>) depicts the ancient origin of GBPs in lineages leading to *Homo sapiens*.](JEM_20182031_Fig1){#fig1}

In humans, seven *GBP* genes and one pseudogene reside in a single cluster on chromosome 1q22.2, with close orthologues present in most anthropomorphic primates ([@bib112]; [@bib141], [@bib142]; [@bib75]; [Fig. 2](#fig2){ref-type="fig"}). The evolution of primate GBPs is likely to yield important insights into human-tropic infections including HIV-1 and HIV-2 that originated via multiple transmissions of simian immunodeficiency viruses across species barriers ([@bib140]). HIV-1 was thought to be introduced into humans by zoonotic spread from Western gorillas and chimpanzees, whereas HIV-2 arrived via Old World monkeys including sooty mangabeys and drills that probably lack a human *GBP5* orthologue capable of restricting HIV-2 infectivity ([@bib69]; [@bib117]; [Fig. 2](#fig2){ref-type="fig"}). Thus, GBP5 might have helped limit HIV-2 pathogenicity within the human population. Rapidly evolving nonsynonymous codon usage in *GBP5* and HIV-2 should highlight the basis for this host--pathogen arms race and reinforce the evolutionary impact of GBPs for pathogen-specific defense among different primate species. A similar arms race likely occurred in Neanderthal and Denisovan genomes, in which the enrichment of *GBP4* and *GBP7* alleles suggests that early hominid orthologues were also positively selected via host--pathogen conflicts ([@bib155]; [@bib35]).

![**Composition of GBP families among closely related primates.** Overlapping genomic contigs for primate *GBP* cluster assembly reveal differences for GBP5 in selected Great Apes versus Old World monkeys. Alignment of the GBP clusters were extracted from the Ensembl database with mRNA transcripts validated for the encoded genes in multiple repositories. Blue regions depict contig regions. Red bars cover individual *GBP* loci.](JEM_20182031_Fig2){#fig2}

In genetically tractable vertebrate models such as mice and zebrafish, the presence of familial *GBP* clusters also dominates, in this case 11 and 8 *Gbp* genes, respectively ([@bib29]; [@bib141], [@bib142]; [@bib72]; [@bib67]). Gbp KO mice were initially reported 7 yr ago ([@bib65]), and engineered deletions in the murine chromosomal 3H1 cluster that harbors *Gbp1 (Gbp2a)*, *Gbp2*, *Gbp3*, *Gbp5*, and *Gbp7* have continued to aid our understanding of innate immunity and host defense by these proteins ([@bib67]). For the 5E5 cluster that contains *Gbp6*, *Gbp8*, *Gbp9*, *Gbp10*, and *Gbp11*, chromosomal deletions have yet to be reported, although loss-of-function siRNA approaches indicate an important role for Gbp6 and Gbp10 in antibacterial immunity ([@bib65]).

Genomic examination of *Danio rerio* has likewise unearthed links between GBPs and the core inflammasome machinery ([@bib142]; [@bib67]; [@bib153]). Some zebrafish *GBP* genes (*zGBP3*, *zGBP4*) encode caspase activation and recruitment domains (CARDs) like those found within the human inflammasome-associated proteins, ASC (apoptosis-associated speck-like protein containing a CARD), NLRP1, and caspase-4 ([@bib142]; [@bib67]; [@bib97]; [Fig. 3 A](#fig3){ref-type="fig"}). Physical and functional interactions between inflammasome proteins and GBPs are seen in zebrafish neutrophils and human macrophages ([@bib142]; [@bib153]). In the protochordate, *Branchiostomata floridae*, *Gbp* genes are fused with death effector domains related to human caspase-8 and FADD (Fas-associated protein with death domain; [@bib142]); these orthologues presage roles for mammalian GBPs in inflammasome-dependent and -independent cell death programs ([@bib98]; [@bib121]; [@bib39]; [@bib91]; [@bib59]). Thus, by comparing sequence and interdomain similarities across multiple genomes, new clues as to how GBPs may operate during infectious and inflammatory disease in humans have emerged.

![**Human GBP domain structure and response to IFNs. (A)** Top: Some GBPs share orthology with core inflammasome components as revealed by domain accretion in other taxa. Zebrafish GBP3 and GBP4 harbor GTPase (G) and C-terminal helical domains (H) fused to CARDs (C). The latter are orthologous to CARD fusions in human NLRP1, ASC, and caspase-4. Bottom: Similar CARD domain surface structures from zebrafish GBP3 (PDB [4IRL](4IRL)) and human NLRP1 (4IFP; <https://www.ebi.ac.uk/pdbe>). **(B)** Crystal structure of human GBP1 bound to the GTP analogue GMPPNP (RCSB Protein Data Bank accession no. 1F5N) reveals a bidomain architecture: N-terminal GTPase and C-terminal helical domains. Two-step GTP hydrolysis shown above. **(C)** GBP mRNA expression levels robustly induced with IFNs from multiple microarray and RNA sequencing studies deposited in the Interferome database and [@bib14]. **(D)** Position of IFN-dependent binding sites for transactivation validated in CHIP-seq ENCODE data from human cells induced with IFN-α or -β (IRF1), IFN-γ (STAT1), or untreated (STAT3, IRF4), or treated with OHTAM/ethanol (STAT3; <https://genome.ucsc.edu>). CP, cysteine protease domains; F, function to find; P, pyrin; N, NACHT domain; LRR, leucine-rich repeat; CHIP-seq, chromatin immunoprecipitation sequencing.](JEM_20182031_Fig3){#fig3}

Biochemical and structural features of the GBPs {#s04}
===============================================

The proteins encoded by these *GBP* loci share similarities with dynamin-like GTPases that undergo guanosine nucleotide-driven self-assembly to form large homotypic complexes ([@bib123]; [@bib38]). In this respect, the GBPs resemble other IFN-induced GTPases including the 21--48 kD immunity-related GTPases (IRGs), 72--82 kD myxoma resistance proteins, and ∼200--285 kD very large inducible GTPases ([@bib66]). Unlike these latter groups, which bind guanosine-5′-triphosphate (GTP) to produce guanosine-5′-diphosphate (GDP), GBPs bind both GTP and GDP with equimolar affinity to also produce guanosine-5′-monophosphate (GMP; [@bib22]; [@bib124]). The physiological importance of this nucleotide preference is currently unknown, but GBP mutants unable to catalyze the production of GMP could be informative in understanding their unique host defense profiles versus other IFN-induced GTPases.

Once nucleotide-bound, GBPs exhibit high intrinsic rates of GTPase and GDPase activity (catalytic rate constant, ∼80--150/min) that occurs in a structurally conserved two-step reaction ([@bib136]; [@bib45]; [Fig. 3 B](#fig3){ref-type="fig"}). This high rate of catalysis is due to an internal GTPase-activating protein region which obviates the need for external GTPase-activating proteins to accelerate substrate hydrolysis for higher-order assembly ([@bib124], [@bib125]; [@bib73]; [@bib1]; [@bib65]; [@bib70]). Such unusual substrate binding can be traced to an atypical TLRD- or TVRD-containing G4 site that makes contact with the purine ring of guanosine nucleotides in the GBP catalytic domain; this differs from the canonical (N/T)(K/Q)xD G4 motif found in other dynamin-like proteins and smaller H-Ras GTPases ([@bib22]; [@bib85]; [@bib141]).

At the primary sequence level, human and mouse GBPs share 40--98% amino acid identity ([@bib141]; [@bib65]). A bidomain architecture comprising an N-terminal catalytic GTPase domain and extended C-terminal helical domain harboring a series of amphipathic α-helices has emerged from crystallization studies and is common to human and mouse GBPs ([@bib126]; [Fig. 3 B](#fig3){ref-type="fig"}). Both halves contribute to formation of the holoenzyme, as C-terminal truncations or GTPase mutants each prevent cooperative self-assembly ([@bib142]; [@bib159]; [@bib58]). This cooperative self-assembly can in some cases lead to extreme supramolecular structures, containing as many as 6,000 monomeric units, being deposited on pathogen-associated membranes ([@bib71]). Such large nanomachines constitute sensory platforms which alert the host to infection and induce antimicrobial pathways, including oxidative and inflammasome components, that contribute to direct pathogen control ([@bib66], [@bib67]). These nanomachines could also act as mechanoenzymes capable of directly disrupting the microbial cell wall or vacuole during pathogen elimination ([@bib91]; [@bib99]; [@bib71]).

Physical engagement of GBPs with microbial surfaces, pathogen-containing vacuoles, and endolysosomal membranes relies on posttranslational modifications within the C-terminal domain. Human and mouse GBP1, GBP2, and GBP5, for example, each possess a CaaX box at the C terminus. 15-Carbon farnesyl or 20-carbon geranylgeranyl hydrophobic groups are covalently added via the cysteine residue in this CaaX motif to facilitate membrane binding. For human GBP1, recent evidence suggests that farnesylation not only helps anchor this protein but also serves as a nucleating template to deposit more GBP1 on the membrane surface ([@bib143]). Partial geranylgeranylation of mouse Gbp1 may serve a similar purpose ([@bib147]). Mutations in or nearby the CaaX motif as well as C-terminal deletions both liberate membrane-bound GBP complexes; they also severely impair cell-autonomous immunity and inflammasome activation ([@bib65]; [@bib70]; [@bib142]; [@bib40]; [@bib122]; [@bib131]). Thus, membrane targeting and lipid binding are centrally important for immune-related GBP functions. To date, other posttranslational switches involving phosphorylation, acetylation, and succinylation have not been reported, although online databases (<https://www.phosphosite.org>) indicate that serine/threonine, tyrosine, and lysine residues are naturally modified in both human and mouse GBPs.

Mobilizing GBPs in cells and tissues {#s05}
====================================

GBPs are among the most abundant ISGs expressed in humans, and they show enormous plasticity in their responsiveness to physiological stimuli. Human GBP1 and GBP5 expression, for example, can be inducibly increased by nearly three orders of magnitude, reaching up to 300,000 molecules per cell within 24 h of IFN-γ exposure ([@bib20], [@bib21]; [Fig. 3 C](#fig3){ref-type="fig"}).

In the absence of acute activating signals, GBPs are typically expressed at low-to-medium basal or tonic levels in immune cells as well as in the stroma of the lung, liver, kidney, digestive tract, brain, and skin ([@bib102]; [Fig. 4](#fig4){ref-type="fig"}). Two notable exceptions are human *GBP6* and *GBP7,* which are constitutively expressed only in the oropharyngeal tract and liver, respectively ([Fig. 4](#fig4){ref-type="fig"}). Human GBP4 is likewise present in nonactivated pluripotent embryonic stem cells, but expression is lost upon differentiation ([@bib165]). Indeed, all seven human GBPs are detectable at low levels by single-cell RNA sequencing throughout preimplantation (\<2--11 reads per kilobase million), with peaks for *GBP1* in epiblasts, *GBP2* in oocysts, and *GBP5* in morula ([@bib168]). These constitutive examples may reflect stage-, cell-, and tissue-specific epigenetic control. In most other settings, however, GBP expression requires robust immune-receptor signaling, including in adult pluripotent lineages such as neural stem cells or neocortical progenitors like radial glia ([@bib82]; [@bib149]). Similar findings emerge in murine systems. Gbps are expressed in numerous parenchymal and stromal cells as well as at least 11 different immune lineages that span phagocytes and innate-like lymphocytes including NKT, B1-, and CD8αα T cells ([@bib166]; [@bib102]). The role of GBPs in the lymphoid lineages has yet to be delineated.

![**Diverse GBP expression under homeostatic and disease conditions.** Left: Homeostatic expression of different GBP proteins varies between human tissues. Heat maps generated from data deposited in the Human Protein Atlas consortium (<https://www.proteinatlas.org/>). mRNA data are shown for GBP7 due to a lack of antibody validation for this GBP. Right: GBP protein expression in human tissues during different disease states from the Human Protein Atlas consortium. Scale values shown in each case below heat maps. N.D., not detectable.](JEM_20182031_Fig4){#fig4}

IFN-γ and IFN-α/β were the first immune signals described for GBP induction ([@bib20]; [@bib27]). They remain the most potent stimuli when compared with equimolar concentrations of other cytokines or TLR agonists in humans and mice ([@bib21]; [@bib13]; [@bib29]; [@bib65]). Multiple gamma-activated sites (GASs) and IFN-stimulated response elements exist within the 5′ cis-regulatory regions of human *GBP* genes that engage STAT and IFN regulatory factor (IRF) complexes, respectively ([Fig. 3 D](#fig3){ref-type="fig"}). Pioneering work by the Darnell group showed that GAS elements were occupied by STAT1 homodimers following IFN-γ treatment, for example, in the human *GBP1* promoter ([@bib25]). De novo synthesis of IRF1 is also obligate for the transcription of several *GBP*s that are classified as secondary response genes because of their IRF1 dependency and cycloheximide sensitivity ([@bib13]). Because of this dependency, *GBP1* and *GBP2* mRNAs typically accumulate ∼4--24 h after IFN exposure. IFN-stimulated response elements also bind heterotrimeric STAT-1/STAT-2/IRF-9 complexes (termed IFN-stimulated gene factor 3; [@bib28]) downstream of IFN-α/β and IFN-λs1-3; thus, some GBPs can respond to type III IFN as well, for example *GBP1* in human keratinocytes ([@bib3]) and multiple GBPs in IFN-λ--treated hepatocytes ([@bib14]; [Fig. 3 C](#fig3){ref-type="fig"}).

The presence of NFKB1 binding sites for Rel-related dimers in some *GBP* promoters extends the inductive stimuli beyond IFNs. Proinflammatory cytokines like IL-1α, IL-1β, or TNF-α each induce human GBP1 expression within isolated and inflamed tissue endothelium, albeit at much lower levels than IFNs; this induction is opposed by vascular endothelial growth factor and basic fibroblast growth factor through unknown mechanisms ([@bib48]; [@bib84]; [@bib103]; [@bib152]). Human GBP1 likewise responds to IL-1β and TNF-α in colonic epithelial cells, whereas both cytokines robustly elicit several mouse Gbps in murine fibroblasts ([@bib105]; [@bib16]). Besides inflammatory triggers, epidermal growth factor receptor--dependent Src and p38 MAPK signaling can also directly induce human GBP1 in glioblastoma targets ([@bib76]). Thus, several cytokines or growth factors mobilize GBPs across different host cell lineages. These findings highlight potential servo-regulatory functions for GBPs outside of the traditional immune system and extend their protective coverage to essentially every major organ system for cell-autonomous defense against infection.

Such widespread responsivity is reinforced in natura by curated expression profiles of 84 cell types and tissues from healthy individuals as well as patients with clinically confirmed diseases ([Fig. 4](#fig4){ref-type="fig"}). Here, human GBP levels are often dramatically heightened by bacterial, viral, or protozoan infection and are markedly altered during auto-inflammation and cancer. Further regulation is conferred by microRNAs and long intergenic noncoding RNAs. Human *GBP2* is a directly down-regulated target of miR-433 in leukemia ([@bib79]), and several mouse GBPs including *Gbp2*, *Gbp3*, *Gbp4*, *Gbp5*, *Gbp6*, *Gbp8*, *Gbp9*, and *Gbp10* are heavily suppressed by long intergenic noncoding RNA--erythroid prosurvival (also known as *Ttc39aos1*) in LPS-stimulated murine macrophages ([@bib8]). How epigenetic regulation of GBP expression impacts their immune activities is still unknown, but it is clear that multiple levels of control govern their responsiveness in specific cell types and tissues.

GBPs in antibacterial defense {#s06}
=============================

Following induction, GBPs confer cell-autonomous immunity against wide variety of microbial pathogens, especially intracellular bacteria that remain a serious medical problem across the globe. *Shigella* and *Salmonella* species, for example, are major contributors to the 1.3 million diarrheal deaths that occur annually ([@bib44]), and *Mycobacterium tuberculosis* accounts for 1.3 million deaths on its own, killing more people than any other pathogen and making it one of top 10 most lethal diseases from any cause ([@bib164]). Clearly, a better understanding of how native immunity combats these bacterial species is a high priority for public health agencies worldwide.

Antibacterial defense was the first function tested across a complete Gbp family, and this activity was the first defect was reported in genetically engineered Gbp1-deficient mice ([@bib65]; see [Table 1](#tbl1){ref-type="table"}). In this study, Gram-positive *Listeria monocytogenes*, a cause of lethal food-borne illness in humans, and *Mycobacterium bovis* BCG, responsible for disseminated mycobacteriosis in IFN-γ receptor--deficient patients ([@bib173]), were examined. Both bacteria are sensitive to IFN-γ--mediated killing, and each serve as an example of how different bacterial lifestyles are adopted within host cells. *L. monocytogenes* escapes its vacuole shortly after uptake and replicates in the host cell cytosol, whereas *M. bovis* BCG lacks a chromosomal region encoding part of the bacterial type VII secretion (T7SS) apparatus needed for escape; hence it remains trapped inside a phagocytic compartment unless the vacuole becomes damaged ([@bib66]; [@bib88]). In IFN-γ--activated mouse macrophages, both bacteria were targeted by GBPs irrespective of their different lifestyles, and translocation of these immune GTPases to the site of microbial replication was obligate for killing, as shown via amino acid substitutions in GBP mutants that interfere with pathogen targeting ([@bib65]; [Fig. 5 A](#fig5){ref-type="fig"}). Such findings fit with the discovery made at The Rockefeller University nearly a decade earlier that IFN-induced GTPases can directly target the bacterial niche, for example, against *M. tuberculosis* ([@bib90]). This discovery led to a model in which IFN-induced GTPases were posited to recognize microbial and/or modified-self components for their recruitment to the "marked" pathogen ([@bib85], [@bib86]). It now serves as a central tenet in the field.

###### Immune phenotypes in GBP KO mice and disease-associated SNPs/gene alterations in humans

  GBP deficiency                                    Disease or immune challenge                                                       Phenotype                                                                                   Reference
  ------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------
  **GBP KO mice**                                                                                                                                                                                                                 
  *Gbp1*^−/−^                                       *L. monocytogenes*                                                                Susceptible to orogastric infection                                                         [@bib65]
  *M. bovis* BCG                                    Susceptible to i.v. infection                                                     [@bib65]                                                                                    
  *T. gondii*                                       Susceptible to s.c. infection                                                     [@bib138]                                                                                   
  *Gbp2*^−/−^                                       *T. gondii*                                                                       Susceptible to i.p. infection                                                               [@bib30]
  *L. monocytogenes*                                Resistant to i.p. infection                                                       [@bib30]                                                                                    
  *F. novicida*                                     Susceptible to s.c. infection and reduced serum IL-18                             [@bib99]                                                                                    
  OMV i.p. challenge                                Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18   [@bib40]; [@bib131]                                                                         
  *Gbp5*^−/−^                                       *L. monocytogenes*                                                                Susceptible to orogastric infection and insensitive to the caspase-1 inhibitor z-YVAD-FMK   [@bib142]
                                                    LPS i.p. challenge                                                                Reduced serum IL-1β plus IL-18 and reduced active caspase-1 in splenic macrophages          [@bib142]
  MDP i.p. challenge                                Impaired peritonitis and reduced active caspase-1 in peritoneal neutrophils       [@bib142]                                                                                   
  Alum i.p. challenge                               Normal peritonitis                                                                [@bib142]                                                                                   
  MSU i.p. challenge                                Normal peritonitis                                                                [@bib142]                                                                                   
  *Gbp*^*chr3*−/−^                                  *T. gondii*                                                                       Susceptible to i.p. infection                                                               [@bib167]
  *L. monocytogenes*                                Resistant to i.p. infection                                                       [@bib167]                                                                                   
  *F. novicida*                                     Susceptible to s.c. infection and reduced serum IL-18                             [@bib99]; [@bib92]; [@bib161]                                                               
  *L. pneumophila*                                  Susceptible to cytosolic ΔsdhA *Lpn* administered oropharangeally                 [@bib81]                                                                                    
  Norovirus                                         Susceptible to peroral infection in combination with *Ifnar1* deficiency          [@bib12]                                                                                    
  OMV i.p. challenge                                Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18   [@bib40]; [@bib131]                                                                         
  LPS i.p. challenge                                Resistant to endotoxemia after poly I:C priming; reduced serum IL-1β plus IL-18   [@bib131]                                                                                   
  **Human GBP SNPs/alterations**                                                                                                                                                                                                  
  *GBP2*                                            Hepatitis B virus                                                                 IFN treatment responsiveness vs. nonresponsiveness                                          [@bib68]
  (41544 A/G)[^a^](#ttbl1n2){ref-type="table-fn"}                                                                                                                                                                                 
  (41556 G/C)[^a^](#ttbl1n2){ref-type="table-fn"}                                                                                                                                                                                 
  *GBP3* (rs7911)                                   Fibromyalgia                                                                      Protective role in pathophysiology of FM                                                    [@bib119]
  *GBP5* (spliced GBP5ta-97 AA truncation)          Cutaneous T cell lymphoma                                                         High isoform expression in tumor tissues and cell lines                                     [@bib37]
  *GBP7* (rs1803632)                                Malaria                                                                           Promoter mutations associated with higher disease incidence                                 [@bib7]

rs, dbSNP database number; MDP, muramyl dipeptide; MSU, monosodium ureate; FM, fibromyalgia.

JSNP, Japanese Single Nucleotide Polymorphisms database.

![**Antimicrobial activities of GBPs. (A)** Targeting of human GBP1 to cytosolic *S. typhimurium* via live epifluorescent imaging in IFN-γ--activated human HeLa epithelium. Bar, 3 µm. Courtesy of A. Maminska. **(B)** Specific cell-autonomous responses of GBPs to different pathogen classes and the downstream consequences of their antimicrobial actions in humans (h), mice (m), and zebrafish (z). **(C)** Involvement of different GBPs from humans, mice, and zebrafish in canonical and noncanonical inflammasome activation elicited by microbial ligands as input signals. Cytokine and prostaglandin secretion plus pyroptosis are identified outputs. Inflammasome cryoelectron tomography structure (3JBL) from <https://www.ebi.ac.uk/pdbe>. MDP, muramyl dipeptide.](JEM_20182031_Fig5){#fig5}

Subsequent work on IFN-induced GBPs over the past 5 yr has extended the targeting paradigm to other intracellular bacteria that are acquired via contaminated food or water, human-to-human transmission, or zoonotic exposure. These include serovars of *Salmonella typhimurium*, *Francisella novicida*, *Legionella pneumophila, Chlamydia trachomatis*, *Yersinia pseudotuberculosis*, and *Brucella abortus* ([@bib50], [@bib51]; [@bib98], [@bib99]; [@bib91]; [@bib36]; [@bib80]; [@bib175]; [@bib24]; [@bib81]; [@bib131]; [Fig. 5 A](#fig5){ref-type="fig"}). GBP recruitment to these bacteria in human or mouse cells often coincides with reduced microbial viability. It can also lead to decreased or altered fluorescence in bacterial strains expressing GFP or RFP transgenes ([@bib77]; [@bib81]) and loss of LPS staining in Gram-negative bacteria, as reported for *S. typhimurium* and *F. novicida* when they become decorated with endogenous Gbp2 or Gbp5 in mouse macrophages ([@bib98], [@bib99]; [@bib91]). Notably, these effects were abolished in *Ifnar1*^−/−^, *Stat1*^−/−^, or *Irf1*^−/−^ cells, underscoring the importance of IFN signaling to elicit GBP expression.

Two major questions arise from GBP recruitment to intracellular bacteria ([@bib66]; [@bib15]). First, what are the structures recognized by these immune GTPases to target the pathogen niche? Second, how do GBPs control infection once they reach this destination? Attempts to answer the first question using bacterial cell surface mutants have shown that the lipid A moiety of Gram-negative LPS is recognized by Gbp5 in mouse macrophages, and that the LPS O antigen is detected by human GBP1 in lung epithelia infected by *Shigella* or *Burkholderia* ([@bib122]; [@bib131]). In neither case, however, was direct LPS binding by GBPs shown. Moreover, GBPs also target Gram-positive *L. monocytogenes,* actinobacteria such as *M. bovis*, protozoan parasites like *Toxoplasma gondii*, and the replication complexes of HIV-1 and murine norovirus ([@bib29]; [@bib65]; [@bib157]; [@bib15]; [@bib69]; [@bib12]), indicating recognition of structures other than LPS.

Among the likely culprits are intraluminal ligands originating from the endolysosomal system ([@bib15]). All GBP-restricted pathogens identified so far either escape from, dwell within, or intersect this system of cargo vesicles and multivesicular body intermediates at some point during their life cycle ([@bib66]; [@bib15]). In addition, pharmacologic agents that invoke sterile endosomal damage in the absence of infection also solicit GBPs to the site of membrane injury ([@bib15]; [@bib36]). Thus, signals emanating from disrupted organelles probably serve as a proxy of infection, with bacterial pore-forming toxins or type III (T3SS) or IV (T4SS) secretion systems triggering the initial damage to help release these ligands in the context of bacterial infection ([@bib15]; [@bib36]; [@bib175]; [@bib81]). An ability to recognize "modified self" was also reported for the IRGs that bind phosphatidylinositides generated directly on the bacterial phagosome by host lipid kinases in IFN-γ--activated macrophages ([@bib151]; [@bib66]). For the GBPs, however, "altered-self" signals arise from inside rather than outside the vacuole and become available for detection only once pathogens escape into the cytosol ([@bib15]).

Following their recruitment to bacteria, GBPs exert distinct antibacterial mechanisms depending on the protein partners they deploy ([Fig. 5 B](#fig5){ref-type="fig"}). Such partners often reflect the antimicrobial machinery expressed in immune versus nonimmune cells ([@bib42]). For example, in IFN-γ--activated mononuclear phagocytes, certain GBPs interact with the phagocyte oxidase complex (phox; NADPH oxidase) as well as proteins involved in autolysosomal killing of bacteria and inflammasome activation ([@bib65]; [@bib142]; [@bib51]; [@bib92]; [@bib36]). Gbp7 binds endogenous gp91^phox^ and p22^phox^, which comprise the native cytochrome *b*~558~ heterodimeric membrane (Nox2) complex, via its C-terminal tail, whereas it engages the cytosolic p67^phox^ subunit via its GTPase domain. In this way, Gbp7 bridges the Nox2 holoenzyme for assembly on listerial and mycobacterial phagosomes. This finding may add mechanistic insight into the discovery made 35 yr ago that IFN-γ represents the coveted "macrophage-activating factor" responsible for priming the respiratory burst against intracellular pathogens ([@bib104]; [@bib87]).

Besides oxidant defense, Gbp7 also binds the cysteine protease Atg4b for potential closure of autolysosomes around bacteria. Mouse Gbp1 and Gbp2 similarly interact with the autophagy-related proteins p62 and galectin-3, respectively, for recruitment to membranes ruptured by *Listeria* and *Legionella* in IFN-γ--activated macrophages ([@bib65]; [@bib51]; [@bib36]; [Fig. 5 B](#fig5){ref-type="fig"}). A comparable interaction may help recruit Gbp2 to ruptured membranes in *S. typhimurium*--infected macrophages; the latter observation led to the idea that GBPs might directly lyse bacteria-containing vacuoles to release intraluminal ligands for inflammasome activation ([@bib98]). However, subsequent work suggests that this release probably occurs after bacteria have already escaped into the cytosol and that the IFN-induced 47-kD IRG family member Irgb10 lyses the bacterial membrane rather than the vacuolar membrane ([@bib91], [@bib92]; [@bib99]; [@bib81]). Thus, several Gbps mobilize membrane-associated defense activities against Gram-positive, Gram-negative, and actinobacteria within immune phagocytes. Such activities often require GTPase activity and C-terminal isoprenylation ([@bib65]). They also operate in vivo where these immune GTPases are expressed within circulating monocytes as well as mouse and human target organs during natural infection and after vaccination ([@bib29]; [@bib93]; [@bib114]; [@bib145]; [@bib170]; [Fig. 4](#fig4){ref-type="fig"}). Importantly, *Gbp1*^−/−^, *Gbp2*^−/−^, *Gbp5*^−/−^, and chromosome 3H1 cluster--deficient (*Gbp^chr3−/−^*) mice are often highly susceptible to these same bacterial infections (see [Table 1](#tbl1){ref-type="table"}).

Additional GBP-related mechanisms protect nonimmune cells that lack some of the armamentarium found in phagocytes ([@bib42]). Human GBP1, for example, binds F- and G-actin ([@bib113]) to potentially interfere with actin-based motility of *Shigella flexneri* and possibly *Burkholderia thailandensis* within IFN-γ--treated fibroblasts ([@bib122]; [@bib162]; [Fig. 5 B](#fig5){ref-type="fig"}). GBP1 enlists a C-terminal RRR motif that acts as a catalyst for hierarchical recruitment of additional GBPs including GBP2, GBP3, and GBP4 to block bacterial dissemination to neighboring cells ([@bib15]; [@bib122]; [@bib162]). The importance of GBPs in this process is underscored by the discovery of a *Shigella* E3 ubiquitin ligase, IpaH9.8, which ubiquitinates several GBP family members for subsequent degradation by the host proteasome ([@bib77]; [@bib122]; [@bib162]). This allows *Shigella* to escape restriction and highlights the selective pressure placed on intracellular pathogens by this class of defense proteins ([@bib89]). A similar strategy applies to the human-tropic bacterial pathogen, *C. trachomatis*, which evades GBP targeting in IFN-γ--activated human epithelia but is detected by multiple Gbps within murine embryonic or NIH3T3 fibroblasts ([@bib51], [@bib52]; [@bib80]). Thus *C. trachomatis* has also invented methods for GBP avoidance within its natural human host.

GBP immunity to parasites {#s07}
=========================

While intracellular bacteria remain the most studied group of pathogens that are restricted by GBPs, apicomplexan parasites such as *T. gondii* provide valuable information on the host defense activities conferred by these immune GTPases. Toxoplasmosis remains an important global health problem with nearly a third of the world's population seropositive for the parasite ([@bib19]). Severe and occasionally lethal infections ensue in patients with AIDS and other immune-compromised individuals because CD4^+^ T cell--driven immunity is critical for controlling *T. gondii* growth. In this context, IFN-γ mobilizes toxoplasmacidal activity in both immune and nonimmune cells ([@bib169]; [@bib57]). Nitric oxide synthase, indoleamine-2,3-dioxygenase, and autophagy-related pathways are all important IFN-γ--induced effectors in multiple cell lineages of humans and mice ([@bib88]; [@bib139]). However, additional mechanisms have recently been added to this list, including GBPs ([Fig. 5 B](#fig5){ref-type="fig"}).

Work by the Pfeffer group initially helped highlight a role for GBPs in response to *T. gondii*. Examination of the murine Gbp family revealed that many members---including Gbp1, Gbp2, Gbp3, Gbp6, Gbp7, and Gbp9---were targeted to the parasitophorous vacuole (PV) in embryonic fibroblasts and macrophages ([@bib29]). The PV derives from the plasma membrane but typically excludes host proteins involved in later lysosomal fusion ([@bib23]); hence recognition of early altered-self signals probably elicits cooperative interactions among different GBPs, as subsequently reported by several groups ([@bib157]; [@bib167]; [@bib71]). Elegant Förster resonance energy transfer and coimmunoprecipitation studies showed that murine Gbp1 directly binds Gbp2 and Gbp5, and that Gbp2 also engages Gbp3 within preformed complexes that are then recruited to the PV membrane ([@bib157]; [@bib71]). Here, several thousand homo- and hetero-oligomeric Gbp complexes form densely packed polyvalent structures which precede loss of PV integrity, followed by direct binding of Gbp2 to the underlying parasite plasma membrane ([@bib71]; [Fig. 5 B](#fig5){ref-type="fig"}). Whether PV disruption results from GBP mechanoenzyme activity is unknown, although *Gbp2* mutagenesis experiments indicate that GTP hydrolysis, multimerization, and isoprenylation are all involved ([@bib70], [@bib71]; [@bib30]). In addition, p62 and the E3 ligases TRAF6 and TRIM21 may help ubiquitinate the PV, enabling its recognition as a damaged organelle and potentially aiding GBP targeting to this altered-self structure in mouse fibroblasts ([@bib138]; [@bib39]; [@bib41]; [@bib132]). p62, NDP52, LC3B, and galectin-8 perform similar functions in IFN-γ--activated human HeLa cells ([@bib139]).

Nearly all GBP convergence on PV membranes occurs with the widely distributed type II and III *T. gondii* strains that are less virulent, whereas virulent type I parasites interfere with sequestration by GBPs, as seen earlier for *Shigella* and *Chlamydia* ([@bib29], [@bib30]; [@bib157]; [@bib70]; [@bib167]; [@bib138]). Secreted parasitic rhoptry proteins (ROP) 16, ROP18, and ROP54 and dense granule antigen 15 (GRA15) are implicated in this process, possibly via direct GBP phosphorylation or indirect STAT3 and STAT6 activation since several of these type I parasite proteins constitute bone fide kinases ([@bib157]; [@bib57]). Additional parasite effectors including TgIST interfere with STAT1 activation, thereby impacting IFN-γ--induced GBP expression ([@bib43]; [@bib111]). Thus host--parasite coevolution reinforces how GBP suppression leads to evasive action by the virulent type I strain. For this reason, most challenge studies in Gbp KO mice have used the less virulent type II strain, against which *Gbp1*^−/−^, *Gbp2*^−/−^, and *Gbp^chr3^*^−/−^ mice have all proved susceptible (see [Table 1](#tbl1){ref-type="table"}).

Are similar defense profiles evident in humans? Preliminary studies using siRNA or chromosomal CRISPR-Cas9 silencing suggest that GBPs can exhibit robust anti-toxoplasma activity in specific human cell types. For example, human GBP1 restricts *T. gondii* growth in IFN-γ--activated primary mesenchymal stem cells and transformed lung epithelia, with PVs clearly targeted in the former but not the latter cell type ([@bib110]; [@bib63]; [@bib127]). In contrast, human HAP1 cells derived from a myelogenous leukemia cell line do not require GBPs to control *T. gondii* despite the fact that these GTPases target PVs during infection ([@bib110]). This suggests additional IFN-γ--induced factors are needed to disrupt PVs in HAP1 cells, which lack orthologues of the membranolytic IRGs found in mice ([@bib94]; [@bib66]). In human foreskin fibroblasts, halting *T. gondii* replication via host cell death occurs independently of GBP1 or GBP2 as well as caspases, receptor-interacting protein kinases, autophagy, or purinergic receptor activation ([@bib106]). Whether other GBPs beside GBP1 and GBP2 participate in host cell death awaits testing. Clearly, understanding which human cell lineages enlist GBP-mediated immunity to restrict the broad cellular tropism of *T. gondii* will be a fruitful area of future investigation.

The role of GBPs in defense against other apicomplexan parasites, including *Plasmodium* species responsible for human malaria, remains functionally untested. However, a genetic association study unveiled a single nucleotide polymorphism (SNP; rs1803632) in the human *GBP7* promoter that correlated with elevated parasitemia, malaria-related anemia, and hyperpyrexia in Cameroon populations ([@bib7]; [Table 1](#tbl1){ref-type="table"}). In mouse models of cerebral malaria, a number of family members including *Gbp3*, *Gbp4*, *Gbp6*, *Gbp7*, *Gbp9*, and *Gbp11* are up-regulated in the liver of animals infected with *P. berghei* ANKA sporozoites, whereas *Gbp2* and *Gbp3* were highly expressed in the infected brain ([@bib10]; [@bib78]). Similar up-regulation was seen in otherwise resistant mice challenged with the kinetoplastid parasite *Leishmania major*, with increased expression of Gbp1 and Gbp5 in the skin, inguinal lymph nodes, spleen, and liver ([@bib144]). Moreover, Gbp1 colocalized with *L. major*--infected sites. Human GBPs are likewise up-regulated in the skin of patients infected with *L. braziliensis* ([Fig. 4](#fig4){ref-type="fig"}). A role for these large GTPases in immunity to cutaneous leishmaniasis therefore seems likely. In contrast, GBPs fail to target *Trypanosoma cruzi* to control parasite growth ([@bib157]). The basis for these different GBP targeting profiles among kinetoplastids is currently unknown. Recognition of specific protozoan structures, subcellular location of individual GBPs, or cell type may all conceivably influence this parasite defense profile in humans as well as in other mammalian hosts.

Antiviral effects of GBPs {#s08}
=========================

Viruses continue to plague the human population, with HIV-1, rotaviruses, chronic hepatitis viruses, and respiratory pathogens such as influenza A among the leading causes of death ([@bib44]; [@bib164]). Some of these viruses are reported targets of GBP-mediated immunity; however, the breadth of antiviral activity is still being delineated ([Fig. 5 B](#fig5){ref-type="fig"}). Early experiments implicated human GBPs in the control of several RNA viruses. GBP1 was found to restrict vesicular stomatitis, encephalomyocarditis, and hepatitis C viruses in IFN-γ-- or IFN-α--treated HeLa cells and GBP1 overexpressing Huh 7 hepatocytes ([@bib5]; [@bib60]). GBP1, GBP3, and a truncated splice isoform of GBP3 that lacks part of the C-terminal domain (GBP3ΔC) also restrict influenza A replication in human lung epithelia ([@bib108]). Notably, influenza inhibition was dependent on GTP binding but not hydrolysis, enabling antiviral activity to proceed in the face of viral antagonists that interfere with direct catalytic activity, such as the NS5B protein of hepatitis C virus ([@bib60]). Lastly, human nonsynonymous polymorphisms in *GBP2* blunt responsiveness to IFN treatment during hepatitis B virus infection, implying that GBP2 activity is protective in these patients ([@bib68]; [Table 1](#tbl1){ref-type="table"}).

More recent work on important RNA viruses responsible for major human epidemics has extended the reach of GBPs to HIV-1. Silencing GBP5 in IFN-γ--treated human monocyte-derived macrophages made them more permissive to HIV-1 infection as shown by increased production of progeny virions and expression levels of mature gp120 ([@bib69]). Human GBP5 hinders processing and incorporation of the viral envelope glycoprotein, presumably at the Golgi since the viral envelope is assembled at this site and anti-HIV activity is abolished in GBP5 mutants defective for isoprenylation, which is required for Golgi anchorage. Furthermore, macrophage GBP5 expression in HIV patients correlated inversely with infectious virus yields, suggesting that GBP-mediated protective mechanisms operate in natura ([@bib69]). These results fit with the evolutionary profiles of primate GBPs discussed earlier in relation to their antiretroviral potential and reinforce the idea that certain GBP family members may interfere with viruses that transit specific compartments, in this case GBP5 located near the Golgi. Other RNA viruses restricted by GBPs include noroviruses, which cause highly contagious gastroenteritis in people ([@bib12]). Noroviruses propagate on membraneous replication complexes that become marked by the autophagy-related LC3 conjugation system resulting in recruitment of Gbp2, along with other GBPs, and disruption of the replication complexes ([@bib12]). Such protection also manifests in vivo; compound *Ifnar1*^−/−^ and *Gbp*^chr3−/−^ mice show diminished survival in murine models of noroviral pathogenesis ([Table 1](#tbl1){ref-type="table"}).

DNA viruses such as Karposi's sarcoma--associated herpesvirus (KSHV) have recently been added to the list of those targeted by GBPs. Here, human GBP1 was found to disrupt the formation of actin filaments needed to translocate KSHV particles into the nucleus ([@bib174]). GTPase activity and dimerization were needed for these anti-KSHV effects. Notably, KSHV encodes a replication and transcriptional activator, RTA, that induces proteasomal degradation of GBP1 as part of an escape mechanism ([@bib174]). This mechanism echoes earlier tactics deployed by *S. flexneri* ([@bib77]; [@bib122]; [@bib162]). Hence immune evasion strategies are shared in certain bacterial and viral species, again highlighting the selective pressure that GBPs place on structurally diverse pathogens.

GBPs in inflammasome activation {#s09}
===============================

GBP-driven destruction of the bacterial, protozoal, or viral niche can liberate products that then trigger innate immunity to potentially protect the host. These products include LPS and double-stranded DNA that activate inflammasomes, which in turn produce pyrogenic cytokines (IL-1β, IL-18) and induce pyroptosis in many cell types, including macrophages, monocytes, splenic and plasmacytoid dendritic cells, T cells, B cells, neutrophils, keratinocytes, and inflamed endothelium ([@bib17]; [@bib67]). To date, the role of GBPs in activation and assembly of the inflammasome complex has been established in immunologically primed mouse macrophages and human monocytes ([@bib67]; [Fig. 5 C](#fig5){ref-type="fig"}). Such activities are compromised in Gbp-deficient mice ([Table 1](#tbl1){ref-type="table"}).

Important early clues pointing to a relationship between GBPs and the inflammasome complex arose from genome-wide phylogenetic analyses ([@bib142]). Hidden Markov Modeling retrieved 594 GBP-related sequences from 91 taxa including orthologues in highly divergent species that harbored CARDs. These CARDs resembled those within the core human inflammasome proteins NLRP1, ASC, and caspase-4 ([@bib142]; [@bib67]; [Fig. 3 A](#fig3){ref-type="fig"}). Similarities extend to the atomic level where crystallization of zebrafish IFN-induced guanylate-binding protein 1 (zGBP3) revealed a six-helix bundle almost identical to that of human NLRP1 and ASC ([@bib62]). By "mining the fossil record," ancestral links between vertebrate GBPs and the core inflammasome machinery involved in both the canonical and noncanonical pathways were therefore established.

Such evolutionary links operate at both molecular and organismal levels. Loss-of-function experiments initially identified human GBP5 and its mouse orthologue as facilitators of NLRP3 inflammasome activation in response to microbial triggers and intact bacteria ([@bib130]; [@bib142]). IL-β secretion and pyroptosis were diminished in GBP5-deficient human monocytes and in Gbp5 siRNA-treated mouse macrophages from C57BL/6J, C57BL/6N, or Balb/c mice ([@bib130]; [@bib142]); the latter experiment ruled out potential strain differences in Gbp1 expression conferred by the chr.3H1 cluster ([@bib146]). Notably, inflammasome defects were most evident in cells primed by IFN-γ compared with those primed by LPS or lipid A ([@bib130]; [@bib142]; [@bib98]; [@bib121]; [@bib91]; [@bib95]). Such differences may reflect higher GBP expression levels or inflammasome activation after IFN-γ induction, which appears to be a common feature of all GBPs tested thus far ([@bib142]; [@bib98]; [@bib121]; [@bib95]; [@bib40]; [@bib161]). Human GBP5 was shown to bind the NLRP3 pyrin domain and accelerate inflammasome complex formation via its own tetrameric assembly, as revealed using GBP5 oligomerization mutants ([@bib142]). By analogy, IFN-γ--induced zGBP4 likewise directly binds ASC via its CARD domain, facilitating assembly of a macromolecular complex that includes caspase-1 in response to *S. typhimurium* infection of zebrafish embryos ([@bib153]; [Fig. 5 C](#fig5){ref-type="fig"}). Hence GBP oligomerization can help drive assembly of complexes with inflammasome proteins across distant vertebrate species; this may extend to inflammatory caspases like human caspase-4, which shares CARD sequence similarities with zebrafish GBPs ([@bib142]; [Fig. 3 A](#fig3){ref-type="fig"}). Such assembly could conceivably take place at cytosolic preassembly sites or after recruitment of these partners onto bacteria themselves ([@bib67]).

In fact, Gbp5 and Gbp2 directly target *F. novicida* for disruption, resulting in release of double-stranded DNA (dsDNA) in mouse macrophages and subsequent activation of the canonical AIM2 inflammasome ([@bib91]; [@bib99]; [@bib161]). Similar results emerge with *L. pneumophila*; Gbp-mediated release of *Legionella* dsDNA stimulated downstream cyclic GMP-AMP synthase--mediated IFN-β production and AIM2 inflammasome-induced pyroptosis. Here, autocrine IFN-β was sufficient for tonic Gbp expression ([@bib81]). Gbp5 may also target outer membrane vesicles (OMVs) from Gram-negative bacteria to activate the noncanonical inflammasome in IFN-β--primed human monocytes, as well as the type III strain of *T. gondii*, to elicit IL-1β release in naive mouse macrophages ([@bib96]; [@bib131]). Thus, targeting GBPs to bacteria and protozoa often releases ligands to elicit canonical or noncanonical inflammasome pathways ([Fig. 5 C](#fig5){ref-type="fig"}), thereby linking cell-autonomous defenses with innate immune signaling further downstream.

These GBP-dependent inflammasome activities manifest in vivo ([Table 1](#tbl1){ref-type="table"}). Bacterial infections that require caspase-1 or caspase-11 for protection also involve GBPs. For example, *Gbp2*^−/−^, *Gbp5*^−/−^, or *Gbp*^*chr3*−/−^ mice exhibit heightened vulnerability to Gram-positive *L. monocytogenes* and to a panel of Gram-negative pathogens, due in part to reduced IL-1β and IL-18 expression ([@bib142]; [@bib99]; [@bib92]; [@bib161]; [@bib81]). *S. typhimurium*, *F. novicida*, and *L. pneumophila* mutants (*ΔSdhA*) that engage the inflammasome within the cytosol also have defects in pyroptosis that may prevent clearance of pathogen-infected cells ([@bib99]; [@bib92]; [@bib161]; [@bib81]). Gbp4-deficient zebrafish likewise fail to control flagellin-expressing *S. typhimurium* infection due to reduced caspase-1 activation and prostaglandin (PG) D2 synthesis ([@bib153]). Flagellin-dependent PG release was initially shown for the murine Naip5-Nlrc4 inflammasome complex ([@bib158]), but it appears that jawed fish can also enlist PGs as bona fide downstream inflammasome mediators in addition to IL-1β and IL-18 ([Fig. 5 C](#fig5){ref-type="fig"}). Whether comparable PG-dependent mechanisms exist in humans has yet to be identified.

Other forms of systemic inflammation incited by microbial products are controlled by GBPs. Inflammasome-related defects in *Gbp2*^−/−^, *Gbp5*^−/−^, and *Gbp^chr3^*^−/−^ mice challenged with LPS or exposed to Gram-negative OMVs include impaired CD11b^+^ macrophage caspase-1 activity, diminished IL-1β and IL-18 production, and delayed mortality during sepsis ([@bib142]; [@bib40]; [@bib131]; [Table 1](#tbl1){ref-type="table"}). In muramyl dipeptide--induced peritonitis models, *Gbp5*^−/−^ mice likewise exhibit neutrophil caspase-1 defects that block IL-18--induced polymorphonuclear neutrophil recruitment ([@bib142]). Thus, GBPs impact inflammatory responses to localized infection and systemic microbial products in part through activation and assemblage of different inflammasome complexes.

It will be interesting to discern whether manipulation of such activities can impact Gram-negative sepsis in humans, a condition that is responsible for 250,000 annual deaths in the United States alone following surgical, burn, or infectious trauma ([@bib56]). While blocking the initial cytokine-mediated hyper-inflammatory phase of sepsis improves survival, patients often undergo a protracted immunosuppressive phase that renders them vulnerable to both primary and secondary infections ([@bib56]). Rescuing "deactivated" monocytes using IFN-γ in individuals with sepsis has been shown to improve antimicrobial defense ([@bib31]). Whether specific GBPs can also be pharmacologically targeted to mobilize IFN-γ--driven host defense while simultaneously avoiding inflammasome-mediated tissue injury is an important and exciting clinical question going forward.

GBPs in metabolic inflammatory diseases and microbiota-driven colitis {#s10}
=====================================================================

Other inflammatory conditions besides sepsis enlist nucleotide binding--leucine-rich repeat (NLR)--mediated cytokine production or eicosanoid synthesis. Metabolic inflammatory syndromes such as nonalcoholic fatty acid liver diseases and obesity as well as with inflammatory bowel diseases (IBDs) are subject to control by NLRP3 and NLRP6 inflammasomes and their product, IL-18, in response to dysregulated microbiota ([@bib171]; [@bib53]). Atherogenesis may similarly be further worsened by NLRP3 inflammasome activation in response to excess cholesterol crystals accumulating within fatty plaques ([@bib34]). GBPs have been implicated in both of these processes.

The gastrointestinal tract functions not only as a place of nutrient uptake but also as a barrier to infection. When innate and acquired immunity is not adequate in maintaining control of commensal flora and food-borne pathogens, these gut infections can lead to several forms of IBD, including Crohn's disease (CD) and ulcerative colitis (UC; [@bib2]). Several reports point to a potential role for the GBPs in human IBD and animal models of colitis. The *Gbp1* locus (also termed *Gbp2a*) resides in a quantitative trait locus susceptibility region for spontaneous enterocolitis in *Il10*^−/−^ Cdcs^C3H/HeJBir^ mice ([@bib26]), and human GBP1 localizes to tight junctions of intestinal epithelial cells in patients with both CD and UC; in this context, GBP1 has been posited to regulate commensal *Escherichia coli*--induced apoptosis and barrier integrity to control gastrointestinal inflammation ([@bib134]). GBP5 stimulates the inflammasome-related activity of NLRP3 and may be involved in the assembly of NOD2 ([@bib142]); mutations in both NLRP3 and NOD2 have been linked to susceptibility to CD in humans ([@bib2]; [@bib156]). In this regard, several GBPs are also up-regulated in the colon during CD and in murine models of microbial colonization of the developing intestine ([@bib100]; [Fig. 4](#fig4){ref-type="fig"}). Hence GBPs could act as regulators of microbiota-driven inflammation due to their involvement in epithelial cell defense and inflammasome responses that are needed for gastrointestinal immunity or dysbiosis. Experiments in Gbp-deficient mice should help establish direct causal links with IBD progression or suppression as well as shifts in microbial consortia of the gut.

An association of GBPs with atherogenesis has recently emerged from murine models of hypercholesterolemia ([@bib47]). *ApoE*^−/−^ mice fed a high-fat Western diet exhibited increased Gbp2, Gbp3, Gbp5, Gbp6, and Gbp7 expression within lesional foam cells ([@bib47]). In *ApoE*^−/−^ macrophages, ex vivo exposure to oxidized low-density lipoproteins elicited high Gbp3 and Gbp6 expression, suggesting that this metabolic stimulus may trigger Gbp induction at a cell-intrinsic level. Whether such expression impacts the development of atherogenic lesions and how different inflammasome subtypes operate during atherogenesis remain untested. This also applies to several other inflammatory and autoimmune disorders such as asthma, psoriasis, arthritis, and Sjögren's syndrome in which heightened GBP expression has been described in human patient samples ([Fig. 4](#fig4){ref-type="fig"}). Some of these IFN-associated diseases are amenable to JAK inhibitors ([@bib101]; [@bib135]). Whether GBPs are involved in the mechanism of action of JAK inhibitors is unknown; however, this is poised to be an active area of clinical investigation in the future.

GBPs in oncogenic surveillance and cancer {#s11}
=========================================

Cancer immune-editing models show IFN-γ--driven surveillance is essential for eliminating tumors and maintaining residual malignant cells in a dormant state ([@bib4]). IFN-γ can also be coopted, however, by certain tumors to escape anti-cancer responses by up-regulating PD-L1 expression ([@bib9]; [@bib116]). Both pro-and anti-tumor roles are therefore likely to result from IFN-γ--dependent gene induction depending on the cancer cell type, clinical context, and the specific ISGs enlisted ([@bib120]).

GBP family members are among the IFN-γ--dependent genes most highly induced in patients with different cancers at various stages of disease or remission ([Fig. 4](#fig4){ref-type="fig"}). Increased tissue expression of human GBP1, GBP2, GBP4, and GBP5 reveals favorable prognostic outcomes with certain tumors, for example, breast, and colorectal cancer, but highly unfavorable associations for others, such as renal cancers ([@bib46]). The basis for this disparity is currently unknown, although poor prognosis in renal cancer may be independent of IFN signaling since both type I and II IFNs exhibit survival benefits for patients with kidney cancer ([@bib115]; [@bib120]).

One explanation for these disparate outcomes involves distinct cellular mechanisms used by different GBP family members. For example, GBP1 binds F-actin to regulate cytoskeletal dynamics ([@bib113]); these interactions may influence cancer cell migration or cell division via effects on mitotic spindle assembly. It could also offer some insight into how GBP1 confers paclitaxel resistance in tumors such as ovarian cancer ([@bib33]; [@bib150]; [@bib160]). Paclitaxel stabilizes the microtubule polymer and protects it from disassembly, whereas GBP1 is thought to prevent cytoskeletal polymerization ([@bib162]). Incorporation of GBP1 into the cytoskeletal network facilitates binding of pro-survival kinases such as PIM1 and NEK6; such interactions may initiate a resistance pathway to paclitaxel ([@bib6]; [@bib32]).

Human GBP1 has also been reported to suppress matrix metalloproteinase 1 expression for glioblastoma and endothelial cell invasiveness, the former in response to EGFR-dependent signaling ([@bib48]; [@bib76]). Subsequent silencing of GBP1 led to metastatic invasion in nu/nu mouse models of glioblastoma multiforme ([@bib74]). Thus, GBP1 has onco-protective effects beyond direct actin remodeling. Other cytoskeletal-independent activities include interactions between the GBP1 C-terminal domain and Hippo signaling transcription factor TEA domain protein that interferes with expression of YAP1--TEA domain protein target genes needed for cellular hyper-proliferation ([@bib154]). This may provide some basis for the ability of GBP1 to act as a tumor suppressor in colorectal cancers which arise from dysregulated Hippo signaling ([@bib16]; [@bib54]).

A similar function has been ascribed to human GBP2, which serves as a p53 target gene elicited together with IRF1 in esophageal squamous cell carcinomas ([@bib49]; [@bib16]). Whether these three proteins form an inhibitory complex is unknown. Gbp2 has also been posited to block Drp1-mediated mitochondrial fission needed for breast cancer invasion ([@bib172]). Clearly more work is needed to establish the molecular basis for how individual GBPs facilitate tumor suppression or inhibition as part of their protective activities. This may extend to cancers having an infectious origin, which currently comprise an estimated 20% of all cases ([@bib18]) and where the antimicrobial effects of GBPs could be highly influential. Last, truncated human GBP5 isoforms lacking the C-terminal 97 amino acids (including the isoprenylation motif) have been associated with some cutaneous T cell lymphomas ([@bib37]; [Table 1](#tbl1){ref-type="table"}). Here, truncated GBP5 could act as a dominant-negative variant by interfering with full-length GBP5 and its partners; indeed, large-scale human studies should begin to unveil cancer-associated *GBP* alleles and inhibitory splice isoforms if these proteins participate in innate immune surveillance and tumor cell killing. Each is a fertile topic for further scientific and clinical exploration.

Conclusions {#s12}
===========

Janeway's influential treatise "Approaching the asymptote?" rekindled interest in the innate immune system as a platform for mobilizing acquired cellular resistance ([@bib61]). Yet like all asymptotes, it remains out of reach. Major gaps in our understanding still exist in terms of how individual cells bring infection and inflammation under control, whether through direct sterilization or indirect tissue tolerance. Indeed, novel aspects of host immune defense continue to emerge in all nucleated cells---not only those of hematopoietic origin---with the GBPs occupying a central position in this newly discovered arsenal ([@bib66], [@bib67]).

With a combined 18 members in humans and mice, the GBPs draw parallels with the 24 TLRs jointly encoded by these two species, but with a different biological purpose and design. Most GBPs seem to act as integrators and even effectors of cell-autonomous immunity once they recognize their microbial targets, unlike TLRs, which constitute classical immune sensors. Importantly, GBPs serve as major protective hubs both inside and outside of the immune system. This ubiquitous profile is reinforced by recent studies in Gbp-deficient mice that reveal susceptibility to intracellular pathogens exhibiting a wide range of cellular tropisms ([Table 1](#tbl1){ref-type="table"}). Whether GBP involvement is equally pervasive in different cancer and inflammatory models awaits inquiry. Clearly much remains to be discovered on this *tour d'horizon* of GBP biology ([@bib89]), especially within the human population where targeted therapeutics of these immune GTPases could eventually serve as novel modifiers of disease ([@bib67]).
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